News Center
Share the latest news with you
2022
2023-03-20
Completed Series D Financing
FDA Granted Orphan Drug Designation to Senaparib in combination with TMZ for the treatment of small cell lung cancer (SCLC)
Dr. Timothy Yap Joined the IMPACT Scientific Advisory Board
Presented phase I dose escalation and dose expansion results of Senaparib in combination with Temozolomide at ASCO 2022
Presented phase I clinical data of Wee1 inhibitor IMP7068 at ESMO 2022
Initiated IND enabling study of a PARP1 selective inhibitor
About Us
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
